Dow Debate: Will Pfizer Crush Merck?

Pfizer and Merck disappointed in 2013 but have made encouraging starts to 2014. Can Pfizer beat Merck, or vice versa?

Feb 17, 2014 at 1:57PM

PFE Total Return Price Chart

PFE Total Return Price data by YCharts.

Merck (NYSE:MRK) and Pfizer (NYSE:PFE) had challenging years in 2013, with both stocks being outperformed by the S&P 500. The broad-based market index delivered a total return of 26.4% over the course of the year, comfortably beating Merck's 25.6% and Pfizer's 22.2% returns.

Performance this year
The first six weeks of 2014, though, have seen the two drugmakers beating major market indices. While the S&P 500 is down 0.5% and the Dow Jones Industrial Average down 2.5%, Merck and Pfizer have delivered respective share price gains of 10.8% and 4.3%. While Merck is comfortably outperforming Pfizer in the first part of 2014, what is the potential for a role-reversal in the pharmaceutical rivalry? Let's see.

A tough fourth quarter
Latest earnings results showed that both companies experienced declines in sales and profits in the fourth quarter, due significantly to competition from generic drugs. Interestingly, Pfizer topped Wall Street expectations with its results, while Merck was only slightly below forecasts. However, both companies' fourth-quarter figures were still well below those recorded in 2012, with Merck's net profit falling by 14% and Pfizer's by 59%.

Generic competition
There is no sign that challenges to the two companies from generic competition for formerly blockbuster drugs is about to disappear. Generic versions of Merck's Vytorin and Zetia (which respectively had total sales $1.6 billion and $2.6 billion in 2013) are expected to be available from 2014 and 2016. Pfizer is expected to face generics for Celebrex and Viagra (total respective sales in 2013 of $2.9 billion and $1.9 billion) by the end of this year and by 2020, respectively.

Clearly, generic competition looks set to have a major impact on both companies in the coming years. However, when considering the pipelines for the two companies, Pfizer looks set to be hit the harder of the two over the next couple of years. While Merck's net profit is forecast to tick upward, from roughly $13.5 billion in 2013 to $14.5 billion in 2015, Pfizer's net profit is expected to fall from about $21 billion to $20 billion over the same time frame.

Pipelines
Still, 2014 has seen encouraging news on Pfizer's pipeline, with the company recently reporting that its experimental drug for advanced breast cancer, palbociclib, hit its midstage study goal. Meanwhile, a pneumonia vaccine, Prevnar 13, could ultimately receive regulatory approval for use in adults aged over 65 (it is already approved for children and adults below the age of 65). These two drugs could contribute more than $4 billion in annual sales and help Pfizer to turn its bottom line around.

Meanwhile, Merck's pipeline continues to show strength, with the company recently reporting a number of encouraging developments. Notably, Merck has announced several collaborations to evaluate novel combination regimens involving its immunotherapy lambrolizumab and initiated a phase 1 study with the drugs in 20 new cancer types.

Shareholder dividends
Pfizer is forecast to grow its dividend per share by 24% over the next two years, which makes Merck's growth of 5.8% over the same time period seem rather pedestrian. Both companies easily beat the S&P 500 yield of 1.96%, with Pfizer's yield at 2.7% and Merck's slightly higher at 3.1% (all TTM). However, should prices stay where they are, Pfizer's higher growth rate in dividend per share should see its yield beat Merck's over the medium term.

Both of these figures are in line with sector peer Bristol-Myers Squibb, which offers a yield of 2.6% and is forecast to grow its dividend by 5.2% over the next two years. This company also faces generic competition but is moving ahead with an exciting pipeline of drugs, as it seeks to move from mass-market manufacturer to a niche, specialist player. Bristol-Myers Squibb has underperformed Merck and Pfizer in 2014 (its stock is up 2.3%) but, like its peers, has beaten the two major indices.

Looking ahead
When it comes to share price, it seems unlikely that Pfizer will be able to crush Merck during 2014. That's not to say, of course, that Pfizer won't do well -- the challenges from generic competition seem to be priced in and there is considerable potential in its pipeline. It's just that Merck could do equally well (if not more so) for the same reasons, plus it should see net profit growth while Pfizer sees net profit decline over the short to medium term.

Both companies could continue to outperform the S&P 500 and the Dow in 2014, but neither is likely to deliver a crushing outperformance of the other. That's unless, of course, there is major positive (or negative) surprise concerning one of the companies' pipeline during the year.

Nine High-Yielding Stocks

One of the dirty secrets that few finance professionals will openly admit is the fact that dividend stocks as a group handily outperform their non-dividend paying brethren. The reasons for this are too numerous to list here, but you can rest assured that it's true. However, knowing this is only half the battle. The other half is identifying which dividend stocks in particular are the best. With this in mind, our top analysts put together a free list of nine high-yielding stocks that should be in every income investor's portfolio. To learn the identity of these stocks instantly and for free, all you have to do is click here now.

 

Peter Stephens has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers